Pharmaceutical Contract Development & Manufacturing Organization Market Size Worth USD 418.65 Billion by 2034 | CAGR: 8.11%

The pharmaceutical contract development & manufacturing organization market size is expected to reach USD 418.65 Billion by 2034, according to a new study by Polaris Market Research. The report “Pharmaceutical Contract Development & Manufacturing Organization Market Size, Share, Trends, Industry Analysis Report By Type (Small Molecule and Large Molecule), By Product, By Service, By Workflow, By Therapeutic Area, By End Use, and By Region – Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The pharmaceutical contract development & manufacturing organization (CDMO) market is witnessing steady growth, driven by rising demand for outsourced drug development, increasing focus on specialty and complex therapies, and expansion of global biopharmaceutical manufacturing infrastructure.

Pharmaceutical companies are increasingly partnering with CDMOs to access advanced formulation, development, and manufacturing capabilities, ensuring efficient, scalable, and compliant production of drugs across clinical and commercial stages.

Pharmaceutical Contract Development & Manufacturing Organization Market Report Highlights

• In terms of type, the small molecule segment dominated the market in 2024, supported by its wide use in generic drugs and oral formulations, which continue to lead global prescription volumes.
• Based on product, the API segment held a major share, driven by pharmaceutical companies’ reliance on CDMOs for scalable, compliant, and cost-effective production of active pharmaceutical ingredients.
• Based on service, the contract manufacturing segment led the market, attributed to increasing outsourcing of production to reduce capital expenditure and ensure regulatory compliance.
• In terms of workflow, the commercial segment accounted for a notable share, fueled by established pharmaceutical companies outsourcing large-scale production to meet global demand efficiently.
• Based on therapeutic area, the oncology segment dominated, driven by rising development of targeted therapies and biologics for cancer treatment.
• In terms of end use, large pharmaceutical companies led the market, due to continuous partnerships with CDMOs to scale production and accelerate time-to-market for both small and large molecule drugs.
• North America dominated the global market in 2024, supported by the strong presence of leading pharmaceutical and biotechnology companies outsourcing drug development and manufacturing to reduce costs and speed up time-to-market.
• Asia Pacific is expected to grow rapidly, backed by the increasing number of global CDMOs establishing production bases in China and India to serve international clients efficiently.
• A few key global players include Boehringer Ingelheim International GmbH, Catalent, Inc., FAMAR Health Care Services, FUJIFILM Diosynth Biotechnologies U.S.A., Inc., Jubilant Pharmova Limited, Lonza Group AG, Patheon Inc. (Thermo Fisher Scientific Inc.), Pfizer CentreOne (Pfizer Inc.), Recipharm AB, Samsung Biologics Co., Ltd., Siegfried Holding AG, Syngene International Limited, Wuxi AppTec Co., Ltd., Vetter Pharma-Fertigung GmbH & Co. KG, and Zhejiang Hisun Pharmaceutical Co., Ltd.

Request a free sample copy or read the full market insights :  pharmaceutical contract development & manufacturing organization market report

Polaris Market Research has segmented the market report on the basis of type, product, services, workflow, therapeutic area, end use, and region:

By Type Outlook (Revenue, USD Billion, 2020–2034)

• Small Molecule          
  • Branded
  • Generic          
• Large Molecule          
  • Biologics
  • Biosimilar

By Product Outlook (Revenue, USD Billion, 2020–2034)

• API     
  • Traditional Active Pharmaceutical Ingredient (Traditional API)
  • Highly Potent Active Pharmaceutical Ingredient (HP-API)
  • Biologics
  • Others
• Drug Product  
  • Oral solid dose
  • Semi-solid dose
  • Liquid dose
  • Others

By Services Outlook (Revenue, USD Billion, 2020–2034)

• Contract Development 
• Contract Manufacturing 
• API Manufacturing
• Finished Drug Products Manufacturing
• Packaging and Labelling 
• Regulatory Affairs 
• Others

By Workflow Outlook (Revenue, USD Billion, 2020–2034)

• Clinical
• Commercial

By Therapeutic Area Outlook (Revenue, USD Billion, 2020–2034)

• Oncology
• Infectious Diseases
• Neurological Disorders
• Cardiovascular Disease
• Metabolic Disorders
• Autoimmune Diseases
• Respiratory Diseases
• Ophthalmology
• Gastrointestinal Disorders
• Orthopedic Diseases
• Dental Diseases
• Others

By End Use Outlook (Revenue, USD Billion, 2020–2034)

• Small Pharmaceutical Companies
• Medium Pharmaceutical Companies
• Large Pharmaceutical Companies

By Regional Outlook (Revenue, USD Billion, 2020–2034)

• North America
  • US
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Netherlands
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Malaysia
  • South Korea
  • Indonesia
  • Australia
  • Vietnam
  • Rest of Asia Pacific
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Israel
  • South Africa
  • Rest of Middle East & Africa
• Latin America
  • Mexico
  • Brazil
  • Argentina
  • Rest of Latin America